| Patient | Leonard Nimoy |
|---|---|
| Date of birth | 1943-03-26 |
| Identifiers | MRN HR-ML017-SYN; SSN (made up) 000-17-6604 |
| Document date | 2026-03-10 |
| Author | Carla Benedetti, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week COPD review after starting tiotropium-olodaterol. [S]
Mr. Nimoy returns four weeks after starting tiotropium-olodaterol two inhalations each morning. He feels a little less tight in the chest in the mornings and has cut his albuterol from once or twice a day to about four times a week. He still has to stop for breath after about 100 meters on level ground. The dose counter shows no missed doses. He has had no flare-up, increase in sputum, fever, or need for antibiotics or prednisone. He has no dry mouth, difficulty passing urine, palpitations, or tremor. He saw the pulmonologist this morning, and his 6-minute walk test was done in the pulmonary function laboratory. He starts pulmonary rehabilitation next week. [S]
| Element | Detail |
|---|---|
| Interval change | Mornings easier; still stops after about 100 meters |
| Reliever use | Albuterol about four times a week, down from once or twice a day |
| Adherence | No missed doses by dose counter |
| Exacerbations | None since intake, and none in the past 12 months |
| Medication tolerance | No dry mouth, urinary difficulty, palpitations, or tremor |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless on walking about 100 meters or one flight of stairs; little cough; small amount of clear morning sputum |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or ankle swelling |
| Genitourinary | Negative | No hesitancy or retention |
| Psychiatric | Negative | Mood steady; no panic with breathlessness |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) | Two inhalations every 4 hours as needed, with a spacer | Respiratory tract route | 2025-09-15 | active | S |
| Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily | Two inhalations once each morning | Respiratory tract route | 2026-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-10 | Body height | 185 | cm | S |
| 2026-03-10 | Body weight | 80.2 | kg | S |
| 2026-03-10 | Body mass index (BMI) [Ratio] | 23.4 | kg/m2 | S |
| 2026-03-10 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-10 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-10 | Heart rate | 82 | /min | S |
| 2026-03-10 | Respiratory rate | 18 | /min | S |
| 2026-03-10 | Body temperature | 36.6 | Cel | S |
| 2026-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 93 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-10 | Six minute walk test | 270 | m | Predicted about 480 m for his age, sex, height, and weight; lower limit about 380 m | Low | S |
Vital signs recorded on 2026-03-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Speaks in full sentences; no use of accessory muscles at rest |
| Lungs | Reduced breath sounds throughout with prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm at 82 per minute; no edema |
| Inhaler technique | Correct with his soft mist inhaler: slow, deep breath with the dose and a ten-second breath hold |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic obstructive pulmonary disease, GOLD 3 (severe airflow limitation), group B, confirmed on spirometry; synthetic modern classification linked to his publicly disclosed COPD | active | confirmed | J44.9 | S — Synthetic modern spirometric classification; the COPD diagnosis itself is D from his own public disclosure. |
| Former smoker, quit about 30 years ago through a cessation program | active | confirmed | Z87.891 | S — Synthetic modern entry linked to his public account of quitting smoking. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | COPD Assessment Test (CAT) | Every visit | Completed today | 19, down from 22 at intake; a change of 2 or more is meaningful |
| Survey | mMRC dyspnea grade | Every visit | Completed today | Grade 3, unchanged |
| Survey | Exacerbation history and GOLD group | Every visit | Completed today | No moderate or severe exacerbation in the past 12 months; group B |
| Examination | Pulse oximetry | Every visit | Completed today | 93 percent at rest on room air |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco for about 30 years |
| Examination | BMI and nutritional status | Every visit | Completed today | BMI 23.4; weight stable |
| Examination | Inhaler technique and adherence | Every visit | Completed today | Correct technique; no missed doses |
| Examination | 6-minute walk test | At pulmonary rehabilitation entry and exit, and for oxygen assessment | Completed today | 270 m at rehabilitation entry; lowest saturation 89 percent |
| Examination | Long-term oxygen assessment | As indicated: resting saturation 88 percent or less, confirmed twice at least three weeks apart | Completed today | Not met: 93 percent at rest and 89 percent at the lowest on exertion; no oxygen prescribed |
| Laboratory | Arterial blood gas | As indicated: resting saturation 92 percent or less, oxygen qualification, or suspected hypercapnia | Not indicated | Resting saturation 93 percent; no sign of hypercapnia |
| Examination | Spirometry | At diagnosis, then at least yearly and with significant clinical change | Up to date | Diagnostic spirometry at intake: post-bronchodilator FEV1/FVC 0.43, FEV1 46 percent predicted; next in one year |
| Laboratory | Alpha-1 antitrypsin | Once, at diagnosis | Up to date | 138 mg/dL at intake, normal; not repeated |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Up to date | 0.18 x10³/µL at intake; no inhaled corticosteroid while there are no exacerbations |
| Examination | ECG and cardiovascular risk assessment | At baseline and after exacerbations | Up to date | Intake ECG in sinus rhythm with no abnormality; blood pressure normal |
| Survey | Mood and comorbidity screening | At diagnosis and yearly | Up to date | PHQ-9 3 and GAD-2 1 at intake; no reflux, sleep, or nutrition concern |
| Referral | Pulmonology consultation | When the diagnosis, severity, or treatment needs specialist review | Completed today | Seen today; GOLD 3, group B confirmed; current inhaler continued |
| Referral | Pulmonary rehabilitation | Stable mMRC 2 or more or CAT 10 or more; within three weeks of any hospital stay for an exacerbation | Referred | Program begins next week |
| Medication safety | Vaccination status | Reviewed yearly | Deferred | High-dose influenza vaccine this past autumn, zoster series complete, Tdap within ten years. PCV20 was planned today but the clinic was out of stock, so it was not given; to be given at the next visit |
| Imaging | Low-dose chest CT | As indicated, or yearly lung cancer screening if eligible | Not indicated | No suspected complication; not eligible for screening, because he quit more than 15 years ago |
Goal progress:
Guideline basis: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020)
Follow-up: Pulmonary rehabilitation from next week. COPD review in two months, after rehabilitation. Next scheduled visit 2026-05-12: three-month COPD review after pulmonary rehabilitation. [S]